To include your compound in the COVID-19 Resource Center, submit it here.

Post-launch report

Post-launch report

Company Product Indication 2005 approval 9-mo sales in 2006 (A)
Amylin (AMLN) Symlin Type I and II diabetes in conjunction with insulin U.S. $30.3
Amylin (AMLN)

Read the full 291 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE